HEPA Lots of potential look for fast tracking on NASH.
Phase 2B Nash trial starts Q3 this year.
No approved drugs for NASH HEPA CRV431 is very safe and efficacy looks very promising.
CEO Foster has brought a blockbuster drug to market in his last company.
For newcomers, Hepion is already moving on to Phase IIb with CRV431 in NASH, based on the low-dose (75mg) results alone, which after 28 days were as good as what Madrigal's P3 lead NASH drug took 12 weeks to achieve.
Also, keep in mind tha HEPAt CRV431 is far and away the best anti-fibrotic in the clinic today. Nothing else compares!
HEPA Another molecule is coming to the pipeline, P2 studies are being planned with CRV431 in multiple myeloma, hepatoma, probably IPF, some anti-viral applications, and so forth, all with enormous potential, based on AI-POWR projections Here's much of what we know about the AI-POWR platform. Development of the platform began in what's called the "AI winter", in the early 1990's, long before others were even thinking about employing AI in drug development. Hepion recently put it into full operation, after nearly thirty years of development, so they are way ahead in this area. The potential cost savings for clinical trials is incalculable!. https://hepionpharma.com/ai-powr/
MDGL 1.8 Billion market cap Phase 3 results so far look mediocre at best 300 million in cash. HEPA 130 million market cap Phase 2B commencing soon. 120 million in cash.